Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Human Immunodeficiency Virus InfectionsHIV Infections

Interventions

BIOLOGICAL

tgAAC09

BIOLOGICAL

tgAAC09

BIOLOGICAL

tgAAC09

OTHER

Formulation buffer

Sterile isotonic buffered salt solution

Trial Locations (5)

Perinatal HIV Research Unit, Baragwanath Hospital, Soweto

Desmond Tutu HIV Centre Cape Town, Cape Town

Medunsa, South Africa

Uganda Virus Research Institute, Entebbe

Zambia-Emory HIV Research Project (ZEHRP), Lusaka

All Listed Sponsors

collaborator

Targeted Genetics Corporation

INDUSTRY

lead

International AIDS Vaccine Initiative

NETWORK

NCT00888446 - Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid | Biotech Hunter | Biotech Hunter